Pharmacological evaluation of novel indole-2-carboxamides as potent lipid-lowering agents in triton-WR-1339-induced hyperlipidemic rats

Zeitschrift fur Naturforschung - Section C Journal of Biosciences

Volumn 64, Issue 9-10, 2009, Pages 619-625

  Al Qirim, Tariq ^a   Shahwan, Moyad ^a   Shattat, Ghassan ^a   Al Hiari, Yusuf ^b   Sheikha, Ghassan Abu ^a   Zaidi, Syed ^c  

^a AL ZAYTOONAH UNIVERSITY OF JORDAN   (Jordan)

^b UNIVERSITY OF JORDAN   (Jordan)

^c STANFORD UNIVERSITY   (United States)

Author keywords

Antihyperlipidemic activity; BMI2C N (4 Benzoylphenyl) 5 methoxy 1H indole 2 carboxamide ; DDMI2C N (9,10 Dihydro 9,10 dioxoanthracen 2 yl) 5 methoxy 1H indole 2 carboxamide

Indexed keywords

RATTUS;

EID: 70449591816     PISSN: 09395075     EISSN: None     Source Type: Journal    
DOI: 10.1515/znc-2009-9-1003     Document Type: Article

References (30)

1. Anila L. and Vijayalakshmi N. R. (2002), Flavonoids from Emblica officinalis and Mangifera indica-effectiveness for dyslipidemia. J. Ethnopharmacol. 79, 81-87.
2. Bhatnagar D. (1998), Lipid-lowering drugs in the management of hyperlipidemia. Pharmacol. Therapeut. 79, 205-230.
3. Bosies E., Heerdt R., Kuknle H. F., Schmidt F. H., and Stach H. (1980), Hypoglycemically and hypolipidemically active derivatives of phenylalkane carboxylic acids. US Patent 150207.
4. Campillo J. E., Torres M. D., Dominguez E., Romero A., and Pérez C. (1994), Ficus carica leaf administration reduces hypertriglyceridaemia in streptozocin diabetic rats. Diabetologia 37, A213.
5. Dasseux J.-L.H. and Oniciu C. D. (2002), Aliphatic, aromatic, and heterocyclic ketone compounds and compositions for cholesterol management and related uses. US Patent 325529.
6. Fiser R. H., Denniston J. C., Rindsig R. B., and Beisel W. R. (1974), Triglyceride secretion rates: use of Triton in the rhesus monkey. J. Nutr. 104, 223-226.
7. Frick M. H., Elo O., Haapa K., Heinonen O. P., Hein- salmi P., Helo P., Huttunen J. K., Kaitaniemi P., Koskinen P., Manninen V., Mäenpää H., Mälkönen M., Mänttäri M., Norola S., Pasternack A., Pikkarainen J., Romo M., Sjöblom T., and Nikkilä E. A. (1987), Helsinki heart study: primary-prevention trial with gemfibrozil in middle aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N. Engl. J. Med. 317, 1237-1245.
8. Frishman W. H. (1998), Biologic markers as predictors of cardiovascular disease. Am. J. Med. 104, 18S-27S.
9. Fujiwara Y., Nishihara H., Nakakoshi T., Hasegawa T., Tagami S., and Kawakami Y. (1997), Elevation of plasma lipid peroxides in non-insulin dependent diabetics with multiple lacunar infarcts. J. Atheroscler. Thromb. 4, 90-95.
10. Ginsberg H. N. (2001), Hypertriglyceridemia: new in- sights and new approaches to pharmacologic therapy. Am. J. Cardiol. 87, 1174-1180.
11. Hikita M., Bujo H., Yamazaki K., Taira K., Takahashi K., Kobayashi J., and Saito Y. (2000), Differential ex- pression of lipoprotein lipase gene in tissues of the rat model with visceral obesity and postprandial hyperlipidemia. Biochem. Biophys. Res. Commun. 277, 423-429.
12. Ishikawa T. and Fidge N. (1979), Changes in the concentration of plasma lipoproteins and apoproteins following the administration of Triton WR 1339 to rats. J. Lipid Res. 20, 254-264.
13. Kalopissis A.-D., Griglio S., Malewiak M.-I., and Rosen R. (1980), Effect of a high-fat diet on rat very low density lipoprotein secretion. Biochim. Biophys. Acta 620, 111-119.
14. Kellner A., Correll J. W., and Ladd A. T. (1951), Sustained hyperlipemia induced in rabbits by means of intravenously injected surface-active agents. J. Exp. Med. 93, 373-384.
15. Khanna A. K., Chauder R., Chandan S., Srivastava A. K., and Kapoor N. K. (1992), Hypolipidemic activity of Achyranthus aspera Linn. in normal and Triton induced hyperlipemic rats. Indian. J. Exp. Biol. 30, 128-130.
16. Khanna A. K., Rizvi F., and Chander R. (2002), Lipid lowering activity of Phyllanthus niruri in hyperlipemic rats. J. Ethnopharmacol. 82, 19-22.
17. Kopin A. S., Carey M., and Wang D. (2006), Altering intestinal motility and absorption of hydrophobic compounds through the use of agonists and/or an- tagonists of the cholecystokinin-1 receptor. US Patent 224869.
18. Lauk L., Galati E.M., Forestieri A. M., Kirjavainen S., and Trovato A. (1989), Mucuma pruriens infusion lowers cholesterol and total lipid plasma levels in the rats. Phytother. Res. 3, 263-264.
19. Malloy M. J. and Kan J. P. (1994), Medical-management of hyperlipidemic states. Adv. Int. Med. 39, 603-631.
20. Nagai T., Tomizawa T., Nakajima K., and Mori M. (2000), Effect of bezafibrate or pravastatin on serum lipid levels and albuminuria in NIDDM patients. J. Atheroscler. Thromb. 7, 91-96.
21. Norioka M., Suzuki M., Ryomoto K., Ikebuchi M., and Harano Y. (2000), Effect of bezafibrate treatment on the altered lipoprotein profiles in hypertriglyceridemic subjects. J. Atheroscler. Thromb. 7, 198-202
22. Otway S. and Robinson D. S. (1967), The effect of the nonionic detergent (Triton) on the removal of triglyceride fatty acids from the blood of the rats. J. Physiol. 190, 309-319.
23. Pérez C., Canal J. R., Campello J. E., Adelaida R., and Torres M. D. (1999), Hypotriglyceridemic activity of Ficus carica leaves in experimental hypertriglyceridemic rats. Phytother. Res. 13, 188-191.
24. Rubins H. B., Robins S. J., Collins D., Fye C. L., Anderson J. W., Elam M. B., Faas F. H., Linares E., Schaefer E. J., Schectman G., Wilt T. J., and Wittes J. (1999), Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of highdensity lipoprotein cholesterol. N. Engl. J. Med. 341, 410-418.
25. Schoonjans K., Staels B., and Auwerx J. (1996), Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J. Lipid Res. 37, 907-925.
26. Schotz M. C., Scanu A., and Page I. H. (1957), Effect of Triton on lipoprotein lipase of rat plasma. Am. J. Physiol. 188, 399-402.
27. Schurr P. E., Schultz J. R., and Parkinson T. M. (1972), Triton induced hyperlipidaemia in rats as an animal model for screening hypolipidaemic drugs. Lipids 7, 69-74.
28. Sher P. M. and Ellsworth B. A. (2004), Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds. US Patent 140474.
29. Stone N. J. (1996), Lipid management: current diet and drug treatment options. Am. J. Med. 101, 40S-49S.
30. Yamada M. (1997), Influence of apolipoprotein E polymorphism on bezafibrate treatment response in dyslipidemic patients. J. Atheroscler. Thromb. 4, 40-44.